Alternatives to tranylcypromine
FDA shortage status is active for tranylcypromine; 1 same-class SPL records are listed below for registry comparison only.
Brand: Parnate
tranylcypromine class peers while FDA lists an active shortage
tranylcypromine (Parnate) is on an FDA shortage listing while 1 other Monoamine Oxidase Inhibitor (MAOI) SPL records remain in this registry peer set (class inventory 2). Labeled indication field for tranylcypromine: Tranylcypromine is used to treat major depressive disorder (MDD) in adults.
Top FAERS reaction fields for tranylcypromine total 293 reports across 10 reactions, set beside phenelzine. Counts are exposure-weighted submissions, not per-patient risk.
About tranylcypromine
Tranylcypromine (Parnate) is a medicine used to treat major depression in adults. It is used when other antidepressants have not worked well enough.
Used for: Tranylcypromine is used to treat major depressive disorder (MDD) in adults. You should only use it if other antidepressants haven't helped. It is not for the first treatment of depression because it can cause serious side effects and has many drug and food interactions.
1 Monoamine Oxidase Inhibitor (MAOI) peers (wide set)
tranylcypromine vs phenelzine · FAERS reaction fields
FAERS top-reaction field "Depression" shows the widest count spread between tranylcypromine and phenelzine in this extract (151-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | tranylcypromine | phenelzine |
|---|---|---|
| Drug Interaction | 68 | 99 |
| Depression | 36 | 187 |
| Serotonin Syndrome | 27 | - |
| Headache | 24 | 136 |
| Hypertension | 24 | 76 |
| Suicidal Ideation | 24 | 51 |
| Atrioventricular Septal Defect | 23 | - |
| Hypertensive Crisis | 23 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
tranylcypromine shortage vs Monoamine Oxidase Inhibitor (MAOI) peer index
Shortage status
FDA shortage listing is active for tranylcypromine (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.
Frequently Asked Questions
Does FDA list a shortage for tranylcypromine while peers remain indexed? ▼
Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for tranylcypromine: see also the generic vs brand label guide when reading Parnate SPL strings.
Read our methodology - how this data is sourced, computed, and verified.